R&G PharmaStudies Co (SZSE:301333) COGS-to-Revenue : 0.62 (As of Mar. 2024)

R&G PharmaStudies Co COGS-to-Revenue Chart

R&G PharmaStudies Co Annual Data
	Trend	Dec13	Dec14	Dec15	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23
COGS-to-Revenue		Get a 7-Day Free Trial					-	0.61	0.62	0.63	0.60

R&G PharmaStudies Co Quarterly Data
	Dec17	Dec18	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
COGS-to-Revenue	Get a 7-Day Free Trial															0.64	0.57	0.62	0.59	0.62

R&G PharmaStudies Co COGS-to-Revenue Calculation

R&G PharmaStudies Co's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

R&G PharmaStudies Co's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

R&G PharmaStudies Co  (SZSE:301333) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

R&G PharmaStudies Co's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

R&G PharmaStudies Co COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of R&G PharmaStudies Co's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

R&G PharmaStudies Co (SZSE:301333) Business Description